EUVIMEDEUVIMED entdecken
Crossref

Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors

Songsong Zhao, Yanyi Qu, Zhiwei Sun, Shuo Zhang, Mingyu Xia, Yan Shi, Jingyi Wang, Yuan Wang, Zhiyuan Zhong iD, Fenghua Meng

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202500911 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Songsong Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and …. Hauptthemen laut MEDLINE: Glioblastoma, Cancer Vaccines, Vaccination, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor vaccines have shown great promise for treating various malignancies; however, glioblastoma (GBM), characterized by its immunosuppressive tumor microenvironment, high heterogeneity, and limited accessibility, has achieved only modest clinical benefits. Here, it is reported that GBM cell lysate nanovaccines boosted with TLR9 agonist CpG ODN (GlioVac) via a strategic vaccination regimen achieve complete regression of malignant murine GBM tumors. Subcutaneous administration of GlioVac promotes uptake by cervical lymph nodes and antigen presentation cells, bolstering antigen cross‐presentation and infiltration of GBM‐specific CD8 + T cells into the tumor. Notably, a regimen involving two subcutaneous and three intravenous vaccinations not only activates systemic anti‐GBM immunity but also further enhances the tumor infiltration of cytotoxic T lymphocytes, effectively reshaping the “cold” GBM tumor into a “hot” tumor. This approach led to a state of tumor‐free survival in 5 out of 7 mice bearing the established GL261 GBM model with complete protection from tumor rechallenge. In an orthotopic hRas‐GBM model induced by a lentiviral plasmid, GlioVac resulted in ≈100% complete tumor regression. These findings suggest that GlioVac provides a personalized therapeutic vaccine strategy for glioblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaCancer VaccinesVaccinationBrain NeoplasmsAdjuvants, ImmunologicNanoparticlesAnimalsMiceCell Line, TumorOligodeoxyribonucleotidesMice, Inbred C57BLCD8-Positive T-LymphocytesFemaleNanovaccines

Stichwörter der Autor:innen

brain tumorimmunoadjuvantlymph node‐targetingnanovaccinespersonalized vaccines

Substanzen

Cancer VaccinesOligodeoxyribonucleotidesCPG-oligonucleotideAdjuvants, ImmunologicNanovaccines

Autor:innen und Institutionen

  • Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123, P. R. China.
  • College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, P. R. China.

ORCID-Profile: Zhiyuan Zhong

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Zhao, S., Qu, Y., Sun, Z., Zhang, S., Xia, M., Shi, Y., Wang, J., Wang, Y., Zhong, Z., & Meng, F. (2025). Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500911

Vancouver

Zhao S, Qu Y, Sun Z, Zhang S, Xia M, Shi Y, et al. Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500911

BibTeX
@article{Zhao2025,
  author = {Zhao, Songsong and Qu, Yanyi and Sun, Zhiwei and Zhang, Shuo and Xia, Mingyu and Shi, Yan and Wang, Jingyi and Wang, Yuan and Zhong, Zhiyuan and Meng, Fenghua},
  title = {Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202500911}
}
Kostenlos starten →